Title: |
Guidelines for diagnosis, treatment and management of urea cycle disorders in China in 2022 |
Edition: |
Original |
Classification: |
Standard guideline |
Field: |
Comprehensive guideline |
Countries and regions: |
China |
Guidelines users: |
Clinical pediatricians, geneticists, neurologists, etc. |
Evidence classification method: |
The guideline involves the determination of clinical problems: the expert group will score the importance of the clinical problems involved in the guideline and judge its importance
Evidence grading method: GREAD evidence grading method, divided into high, medium, low, and very low. The expert group evaluates the research evidence corresponding to the clinical problem; the recommendation opinions of the relevant items are completed according to the strength of the evidence: strong recommendation, recommendation and suggestion
For related issues that are not supported by clinical evidence: the expert group will discuss and reach a consensus, and also complete the recommendations of related items: strong recommendations, recommendations and suggestions
|
Development unit: |
China rare diseases Alliance |
Registration time: |
2021-09-13 |
Registration number: |
IPGRP-2021CN295 |
Purpose of the guideline: |
Patients with UCDs in China still have unmet medical needs, which are rare diseases, clinical misdiagnosis, diagnosis delays, high mortality and disability rates, and no standardized long-term management. We hope to facilitate the standard management of UCDs by refer this new guidelines. |